Week In Review: Three China In-Licensing Deals Add Up To $662 Million
April 03, 2021 at 15:56 PM EDT
Simcere Pharma of Nanjing announced a $292 million agreement to develop a proposed Kazia Therapeutics treatment for glioma in Greater China. Qihan Biotechnology raised $67 million in a Series A++ round to advance its portfolio of cell therapies.